Kent Kresa to Retire From MannKind's Board of Directors; Steven B. Binder to Be Appointed to the Board
Kent Kresa to Retire From MannKind's Board of Directors; Steven B. Binder to Be Appointed to the Board
"We are sincerely grateful for two decades of invaluable leadership that Kent has provided the Board of Directors," said James S. Shannon, Chairman of the Board. "We are looking forward to Steve joining the Board as he was instrumental in providing financial stewardship to MannKind during his tenure and helped bring MannKind into its current era with multiple revenue streams and healthy pipeline progression."DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that Kent Kresa has decided to retire from MannKind's Board of Directors effective September 30, 2024. In addition, the Board of Directors has appointed Steven B. Binder to the Board, also effective September 30, 2024.
2024年8月14日，康涅狄格州丹伯裏和加利福尼亞州WESTLAKE VILLAGE，曼恩凱德生物醫療公司（納斯達克股票代碼：MNKD）宣佈，該公司專注於開發和商業化用於治療內分泌和孤兒肺病患者的創新吸入療法產品和設備，並於2024年9月30日起，Kent Kresa決定從曼恩凱德的董事會中退休。此外，董事會已於同日任命Steven b. Binder加入董事會。
Kresa, who has served on MannKind's Board of Directors since June 2004, was Chairman from 2016 until December 2020. Upon his retirement from the MannKind Board, Mr. Kresa will continue to be associated with the company in the capacity of Chairman Emeritus.
Kresa自2004年6月以來一直擔任MannKind董事會成員，並於2016年至2020年12月擔任主席。在退出曼恩凱德董事會後，Kresa先生將繼續擔任公司董事長榮譽職務。
Binder previously served as MannKind's Chief Financial Officer from July 2017 until April 2024 and currently serves as Executive Vice President, Special Projects. Mr. Binder will remain in that role until he joins the Board of Directors on September 30, 2024, after which he will no longer be an employee of the Company.
Binder曾於2017年7月至2024年4月擔任曼恩凱德首席財務官，目前擔任執行副總裁、特殊項目。Binder先生將保持這一職位，直到在2024年9月30日加入董事會後，他將不再擔任公司員工。
"We are sincerely grateful for two decades of invaluable leadership that Kent has provided the Board of Directors," said James S. Shannon, Chairman of the Board. "We are looking forward to Steve joining the Board as he was instrumental in providing financial stewardship to MannKind during his tenure and helped bring MannKind into its current era with multiple revenue streams and healthy pipeline progression."
曼恩凱德董事會主席詹姆斯·S·香農說：「我們對Kent過去二十年爲董事會提供的寶貴領導力真誠感激。我們期待Steve的加入，他在擔任財務長期間爲曼恩凱德提供了重要的財務管理，並幫助曼恩凱德進入了目前擁有多個營業收入來源和健康的管道發展的時代。」
With the addition of Binder, there will remain nine total members of the MannKind Board of Directors.
加入Binder後，曼恩凱德董事會成員總數將保持爲9人。
About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
曼恩凱德生物醫療公司（Nasdaq：MNKD）專注於爲那些患有內分泌和孤兒肺病的患者開發和商業化創新吸入治療產品和設備。
我們致力於利用我們的配方能力和設備工程的技術，減輕糖尿病，非結核分枝桿菌（NTM）肺病，肺纖維化和肺動脈高壓等疾病的負擔。我們的標誌性技術——乾粉配方和吸入設備——可以快速，方便地向肺的深處輸送藥物，從而在目標疾病的治療方面產生局部或進入系統循環的作用，具體取決於治療目標。
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.
我們致力於利用我們的配方能力和設備工程專業知識減輕糖尿病、非結核分枝桿菌（NTM）肺病、肺纖維化和肺動脈高壓等疾病的負擔。我們的標誌性技術——乾粉製劑和吸入設備——爲藥物快速、便捷地輸送到深層肺部提供了可能，這些藥物可以在當地發揮功效，也可以進入系統循環，具體取決於治療指示。
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
在曼恩凱德生物醫療的全國性合作團隊的熱情協作下，我們的使命是讓人們掌控自己的健康和自由生活。
Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, X or Instagram.
請訪問mannkindcorp.com獲取更多信息，並在LinkedIn、Facebook、X或Instagram上關注我們。
MANNKIND is a registered trademark of MannKind Corporation.
曼恩凱德生物醫療是曼恩凱德的已註冊商標。
For MannKind:
Christie Iacangelo
Corporate Communications
(818) 292-3500
Email: media@mnkd.com
Investor Relations
(818) 661-5000
Email: ir@mnkd.com
對於曼恩凱德生物醫療:
電子郵件：media@mnkd.com
企業通訊
（818）292-3500
電子郵件：ir@mnkd.com
投資者關係
(818) 661-5000
電子郵件：ir@mnkd.com
Source: MannKind
來源：曼恩凱德生物醫療
